96 - Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs

URLi is a novel prandial insulin lispro formulation developed to more closely match physiological insulin secretion. This randomized, double-blind, 4-period, crossover study, compared the PK and glucodynamics (GD) of URLi, insulin lispro (IL), insulin aspart (IA) and fast-acting insulin aspart (FA) after a test meal in 68 adults with type 1 diabetes (T1D), after single individualized SC dose. Twelve healthy subjects provided the “normal” insulin secretory and glucose response to the test meal.